BIRC5 and breast cancer: Survivin is a marker of poor prognosis [10, 11] and is commonly associated with enhanced proliferative index [12], reduced levels of apoptosis [13], resistance to chemotherapy [14–16], and increased rate of tumor recurrence [17] across multiple tumor types, including breast cancer.